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 Here, we review the functional roles of cyclic ADP-ribose and CD38, a 
transmembrane protein with ADP-ribosyl cyclase activity, in mouse social behavior via 
the regulation of oxytocin (OXT) release, an essential component of social cognition. 
Herein we describe data detailing the molecular mechanism of CD38-dependent OXT 
secretion in CD38 knockout mice. We also review studies that used OXT, OXT receptor 
(OXTR), or CD38 knockout mice. Additionally, we compare the behavioral 
impairments that occur in these knockout mice in relation to the OXT system and CD38. 
This review also examines autism spectrum disorder (ASD), which is characterized by 
social and communication impairments, in relation to defects in the OXT system. Two 
single nucleotide polymorphisms (SNPs) in the human CD38 gene are possible risk 
factors for ASD via inhibition of OXT function. Further analysis of CD38 in relation to 
the OXT system may provide a better understanding of the neuroendocrinological roles 
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 Oxytocin (OXT), a nonapeptide, is secreted into the brain by the dendrites or 
axons of the oxytocinergic neurons located in the paraventricular and supraoptic nuclei 
of the hypothalamus (Brownstein et al., 1980; Neuman et al., 1994 and 1996; Russell et 
al., 2003; Ludwig and Leng, 2006; Ross and Young, 2009). OXT regulates several 
complex social behaviors (Carter, 2003: Insel and Fernald, 2004; Donaldson and Young, 
2008; Carter et al., 2009; Skuse and Gallagher, 2009; Ebstein et al., 2009; Insel, 2010; 
Higashida et al., 2007 and 2010). In humans, intranasal OXT may promote trust 
(Kosfeld et al., 2005), generosity (Zak et al., 2007), increased gaze to the eye region 
(Guastella et al., 2008a), inferring the emotions of others (Domes et al., 2007; Guastella 
et al., 2010; Kiss et al., 2011) and face recognition (Rimmele et al., 2009). Intranasal 
OXT has been proposed as a potential therapy to improve social deficits and has few, if 
any, negative side effects. (Yamasue et al., 2009; Ebstein et al., 2009: Munesue et al., 
2010; MacDonald et al., 2011; Bartz et al., 2011). In rodents, OXT is highly involved in 
social interactions, social recognition, pair-bonding, and maternal behavior (Winslow 
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and Insel, 2004; Insel and Fernald, 2004; Young and Wang, 2004; Young, 2007; 
Neumann, 2008; Donaldson and Young, 2008; Insel, 2010; Higashida et al., 2010). In 
addition, animal studies have shown that increased levels of OXT during the early 
postnatal period may affect behavior, and these effects may last into adulthood (Carter 
et al., 2009). Subcutaneous administration of low doses of OXT also facilitates social 
recognition (Popik et al., 1992). Two mouse models with either OXT or OXT receptor 
(OXTR) gene knockouts (Oxt?/? or Oxtr?/?, respectively) show signs of profound social 
amnesia (Nishimori et al., 1996; Ferguson et al., 2000; Takayanagi et al., 2005; Crawley 
et al., 2007; Macbeth et al., 2010; Sala et al., 2011), which was rescued in the OXT 
knockout mice by the administration of OXT. These observations suggest that OXT 
plays an important role in social behavior via the stimulation of the OXTR during brain 
development and throughout the juvenile and adult life-stages (Ahern and Young, 2009; 
Carter et al., 2009; Insel, 2010).  
 In this review, we first discuss the roles of CD38 and ADP-ribosyl cyclase in 
the hypothalamus in the regulation of social behavior. This discussion is primarily based 
upon studies that showed how the reintroduction of CD38 into CD38 knockout mice 
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affects the release of OXT. We further examine results obtained from studies in which 
OXT and OXTR knockout mice were used to analyze the interaction between CD38 and 
OXT. Finally, we focus on single nucleotide polymorphisms (SNPs) of the human 
CD38 gene in relation to autism spectrum disorders (ASD).  
 
2. CD38 and cyclic ADP-ribose  
Recently, we reported that CD38, a type II transmembrane protein, controls 
leukemia malignancy and is a marker of HIV infection in blood cells (Malavasi et al., 
2008). It is also required for normal social behavior in mice (Jin et al., 2007). CD38 
possesses ADP-ribosyl cyclase activity (Lee, 2001; Higashida et al., 2001a and 2007; 
Boittin et al., 2003; Guse, 2005) that produces cyclic ADP-ribose (cADPR) from 
β-NAD+, also known as Vitamin B3, an abundant substrate in the brain (Denu, 2005). 
cADPR is a potential intracellular second messenger and a cofactor for the movement of 
Ca2+ through Ca2+-permeable channels (Ca2+-induced Ca2+-release, CICR; Lee, 2001; 
Higashida et al., 2001a and b; Endo, 2009) from ryanodine-sensitive Ca2+ pools, 
resulting in an increase in cytosolic free Ca2+ concentrations ([Ca2+]i). Thus, it is 
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possible that cellular events such as secretion or cell migration depend on the formation 
of cADPR. We have recently shown that CD38 is required, as shown by the decreased 
formation of cADPR and by CICR, for some social behaviors in mice via the regulation 
of OXT secretion from the hypothalamus and pituitary (Jin et al., 2007; Higashida et al., 
2010; Salmina et al., 2010). 
 
3. CD38 knockout mice   
 Mice lacking the CD38 gene (CD38-/-) are viable, fertile, grow well, and gain 
weight (Kato et al., 1999; Liu et al., 2008) from the dam’s milk during infancy and from 
solid food after weaning. CD38-/- mice showed no deficits in lactation/milk ejection. 
Moreover, Nishimori et al., (1996) reported that mice lacking Oxt are viable and fertile. 
Although all offspring die shortly after birth because of the dam’s inability to provide 
milk, postpartum injection of OXT into these Oxt-deficient dams restores milk ejection 
and rescues the offspring (Nishimori et al., 1996). Similarly, Oxtr-/- mice are viable and 
have no obvious defects in fertility or sexual behavior. In addition, dams exhibit normal 
parturition, but display defects in lactation and maternal nurturing (Takayanagi et al., 
 8 
2005; Sala et al., 2011). These results indicate that, in the OXT/CD38/OXTR signaling 
pathway, OXT and OXTR are not essential for normal parturition but are required for 
milk ejection, while CD38 is not critically involved in reproduction.  
 CD38-/- male pups on postnatal day 7 had significantly higher levels of 
locomotor activity, compared to wild-type individuals, during the first 3 min after 
separation from the dam when they were examined individually in a grid-crossing test 
performed in an observation chamber (Liu et al., 2008). Both the CD38-/- and CD38+/+ 
pups emitted ultrasonic vocalization (USV) upon isolation. The USV calls per 2-min 
session were less frequent (an average reduction of 38%) in CD38-/- pups than in 
wild-type controls (Liu et al., 2008). The properties of the USVs were similar in both 
groups; the frequency was approximately 70 kHz and the mean duration was 
approximately 60 ms. These results are consistent with previous observations in Oxt-/- 
and Oxtr-/- mice (Nishimori et al., 1996; Takayanagi et al., 2005; Sala et al., 2011). 
Interestingly, the degree of disruption of infant behavior appeared to be mild in CD38-/- 
mice compared with the two OXT-related knockout mouse strains (Higashida et al., 
2010). To confirm this, the isolation-induced locomotor activity of four pups on the 
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interacting plate (no physical contact but some interaction, e.g., USVs) was observed 
simultaneously for 18 min. The CD38-/- pups exhibited higher locomotor activity than 
the control pups (Liu et al., 2008). These observations suggest that CD38-/- pups retain 
the ability to interact socially with others.  
 Young male, adult mice investigate intruder females via olfaction in a 
stereotypic fashion and habituate after repeated encounters (Ferguson et al., 2000). 
CD38+/+ males that experienced repeated pairings with the same conspecifics showed a 
significant decline in the time spent investigating the female upon subsequent 
presentations of the same animal. This was not due to a loss of interest, but to a retained 
memory of the paired female?Ferguson et al., 2000). The adult males did not need to 
further investigate the intruder females because they recognized the paired female as 
familiar. In contrast, CD38-/- males showed sustained high levels of investigation at 
every encounter with the same female (Jin et al., 2007). This abnormality in social 
memory found in CD38-/- mice is due to the males’ amnesia with respect to conspecifics. 
This amnesia resembles the memory deficit observed in Oxt-/- and Oxtr-/- mice 
(Ferguson et al., 2000; Takayanagi et al., 2005). 
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 In maternal behavior tests, wild-type dams retrieved five of their biological 
pups precisely and quickly (average latency, 43 ± 3 s) from a remote area of their home 
cages to a restricted area (Jin et al., 2007; Higashida et al., 2010), while CD38-/- dams 
took a significantly longer time to begin retrieval (average latency, 76 ± 8 s; p < 0.01; 
Lopatina et al., 2011) and moved around, suggesting that their interest was drawn to 
things other than their pups. In addition, CD38-/- dams often dropped the pups during 
retrieval, suggesting that they did not remember the way to the nest and resulting in the 
pups becoming scattered to multiple locations. CD38-/- dams fed the pups in their nest 
30 min or more after the stressful perturbation. These results indicated clear 
(neglect-like) abnormalities in the maternal nurturing behavior of CD38-/- postpartum 
mice under stressful conditions such as separation. However, this behavior improved 
considerably upon reproductive experience (Lopatina et al., 2011). The impairment of 
retrieval reported in Oxtr-/- dams is similar to that observed in CD38-/- females.  
  In comparison with wild-type mice, CD38-/- mice have reduced OXT levels in 
the plasma and cerebrospinal fluid (CSF) (Jin et al., 2007) but elevated levels in the 
hypothalamus and pituitary tissues. These observations indicate that, although OXT is 
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produced and packaged into the vesicles in the hypothalamic neurons and posterior 
pituitary nerve endings in CD38-/- mice, it is not sufficiently released into the brain and 
bloodstream. The behavioral phenotype of CD38-/- mice could be normalized by a 
single subcutaneous OXT injection because OXT is able to enter into the brain, 
probably through the blood–brain barrier (see Supplementary Fig. S7 of Jin et al., 2007). 
We used a genetic approach to re-express CD38 by infusing a virus carrying the human 
CD38 gene into the third ventricle of knockout mice. This procedure resulted in the 
normalization of the plasma and CSF OXT levels, thereby normalizing social memory 
(see Fig. 2 of Jin et al., 2007). This indicates that the mechanisms underlying social 
behavior require CD38-dependent OXT secretion (Fig. 1). 
 Interestingly, argine vasopressin (AVP) release is relatively insensitive to the 
CD38 null mutation. Because OXT and AVP neurons are relatively distinct from each 
other but are in the same SON and PVN areas of the hypothalamus, OXTnergic and 
AVPnergic neurons could be differentially controlled by CD38. It is not clear why 
CD38 mutation is insensitive to AVP neurons. In addition, given the role of cADPR in 
mobilizing Ca2+ from stores, additional neurotransmitter or peptide systems could be 
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affected, because OXT and serotonin are colocalized in the brain, as has been shown in 
mice by Yoshida et al. (2009). The answer to these conundrums may lie in an inability 
to affect the depolarization-induced dopamine release in the striatum. The detection of 
dopamine by microdialysis was not impaired in CD38-/- mice, demonstrating the 
specific involvement of CD38 in the OT secretion pathway in the 
hypothalamohypophysial neurons. However, we have no additional data on the CD38 
regulation of other transmitters that contribute to social behavior,at this moment. 
 Surprisingly, the plasma OXT concentration in CD38-/- pups at 1 - 3 weeks of 
age does not decrease but is similar to that in CD38+/+ mice of the same age (Liu et al., 
2008). However, as expected, at 2 months of age (young adult) following weaning, 
there is a significantly lower plasma concentration of OXT in CD38-/- mice than in 
CD38+/+ mice. This decrease in OXT concentration following weaning occurs only in 
CD38-/- mice, suggesting that the switch from the juvenile to the adult stage is a critical 
period for regulating plasma OXT concentrations. Mammary milk was the sole food 
source for CD38-/- pups in this study, as only milk curd was found in the stomachs of 
the offspring born to CD38-/- females (Liu et al., 2008). This is considerably different 
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from the findings in pups born to Oxt-/- and Oxtr-/- females (Nishimori et al., 1996; 
Furguson et al., 2000; Takayanagi et al., 2005; Crawley et al., 2007). OXT was 
abundant in the mammary gland tissue and milk of the lactating dams in the CD38 
wild-type and knockout mice (Fig. 4 in Higashida et al., 2010). Plasma OXT appears to 
be controlled from different sources during the different life-stages. During the fetal 
stage, the fetus can obtain OXT from the placenta, which is linked to the mother, 
because OXT is transported to the fetus through the blood–placenta barrier (Malek et al., 
1996). During the infant stage (suckling stage), the dams provide OXT to the pups from 
milk until weaning. Although the OXT in milk is degraded during digestion, because 
milk is the only food source for the pups during lactation, we speculate that suckling is 
the sole exogenous origin of plasma OXT during this time. During the adult stage 
(post-weaning stage), plasma OXT is derived entirely from endogenous synthesis and 
secretion. OXT levels remain high in wild-type mice during all developmental stages. In 
contrast, OXT levels decrease significantly after weaning in CD38 knockout mice (Liu 
et al., 2008; Fig. 3 in Higashida et al., 2010); this difference suggests a mechanism for 
why CD38-/- mice show different pathological phenotypes at each life-stage (Higashida 
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et al., 2010). 
 
4. ADP-ribosyl cyclase activity 
 In the central nervous system, the ADP-ribosyl cyclase activity corresponding 
to CD38 was detected at very high levels in the hypothalamus (see Supplementary Fig. 
S11 of Jin et al., 2007). In the hypothalamus, the ADP-ribosyl cyclase activity in 
1-week-old mice was 6% of that in 2-month-old CD38+/+ mice (Liu et al., 2008). 
Furthermore, ADP-ribosyl cyclase activity in CD38+/+ mice was significantly higher 
than in age-matched knockout mice. CD38+/+ mice showed significantly higher levels 
of ADP-ribosyl cyclase activity in the hypothalamus from the second week of life 
onward, and the difference in comparison with CD38-/- mice increased markedly 
(Higashida et al., 2010).  
 We recently showed that CD38 is involved in the Ca2+ concentration increase 
in a protein kinase C-dependent manner (Lopatina et al., 2010). In addition, heat, 
together with cADPR, contributes to the elevation of Ca2+ levels (Amina et al., 2010), 
likely due to the activation of Ca2+ permeability through transient receptor potential 
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melastatin 2 (TRPM2) cation channels (Fig. 1). This has been shown in cultured 
NG108-15 neuroblastoma × glioma hybrid cells (Nirenberg et al., 1983). It is unknown 
if this occurs in the intact mammalian hypothalamus.  
The role of ADP-ribosyl cyclase/CD38 in the regulation of OXT secretion 
through cADPR-mediated intracellular calcium signaling has been demonstrated in 
adult mice (Salmina et al., 2010). We observed both lower and similar levels of 
ADP-ribosyl cyclase activity in the hypothalamus and pituitary of 1-week-old CD38+/+ 
and CD38-/- pups (Liu et al., 2008). Based on these observations, we speculate that the 
levels of ADP-ribosyl cyclase activity would also be relatively low at the fetal stage, 
suggesting that the maintenance of plasma OXT in the fetus and infants relies on 
exogenous sources such as the placenta or maternal milk. However, this hypothesis 
needs to be empirically tested. After weaning, the intrinsic activity of ADP-ribosyl 
cyclase in CD38 knockout mice remains low, resulting in the relatively low levels of 
endogenous OXT release during development to the adult stage. This affects the social 
recognition behavior in the adult animals, as suggested by the long-term effects of OXT 
(Carter et al., 2009; Bridges, 2008). Considering these results in mice, we examined the 
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role of CD38 in the human brain and in human social behavior relative to ASD.  
 
5. Human CD38  
 CD38 mRNA expression in the human brain was examined by quantitative 
RT-PCR using commercially available human brain mRNA templates. The highest level 
of CD38 was found in the hypothalamus (Munesue et al., 2010). The human CD38 
protein was detected (post-mortem) in the hypothalamus of Japanese and American 
human brains by immunoreactivity to the anti-human CD38 antibody. These results 
provide evidence that a similar role for CD38 in the regulation of OXT secretion and 
social behavior is possible in the human hypothalamus.  
 The human gene for CD38 is located on chromosome 4 at position p15 
(Nakagawa et al., 1995; Nata et al., 1997; Malavasi et al., 2008) and consists of 8 exons, 
spanning a genomic stretch of 70.5 kb (Fig. 2). In the first set of cohort studies, these 8 
exons and their flanking introns were screened for single nucleotide polymorphisms 
(SNPs) and mutations in 29 unrelated ASD subjects and in 201 non-clinical control 
subjects from the Kanazawa area in Japan (Figs. 2 – 4). The ASD patients fulfilled the 
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diagnostic criteria for ASD found in the Diagnostic and Statistical Manual for Mental 
Disorders, Fourth edition (DSM-IV) and the CASK criteria for ASD, We detected 12 
previously reported SNPs and 5 novel SNPs or mutations, with and without amino acid 
alterations, in ASD subjects and/or control subjects (Fig. 2).  
 
6. Human CD38 intronic rs3796863 SNP  
 By examining CD38 SNPs from another subclass of ASD, the rs379863 (C > 
A) SNP in CD38 intron 7 showed a significant association with high-functioning autism 
(HFA) in individuals of American (p < 0.005, n=104) or non-Japanese (p = 0.23, 
n=188) descent. The DNA samples examined in this study were obtained from the 
Autism Genetic Resource Exchange (Geschwind et al., 2001; Anitha et al., 2008) and 
the Hamamatsu Medical University Hospital (Munesue et al., 2010). This is one of few 
common variants which may contribute to the genetic susceptibility to HFA (Nakamura 
et al., 2008; Wermter et al., 2010). Based on the results of our SNP analysis and 
haplotype transmission disequilibrium test, the C allele of rs3796863 in CD38 may be a 
protective allele, and the A allele may be a risk allele in American HFA cases (Fig. 4 in 
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Munesue et al., 2010; Fig. 5). Work by Lerer et al., (2010), showed that rs3796863 is 
significantly associated with low-functioning autism, but not necessarily HFA. Thus, 
this SNP may have a role in the pathogenesis of autism. 
 Because the allele frequency of SNP rs3796863 is 0.3, this variant is common. 
Very recently, common variants on chromosome 5p14.1, together with 6 meaningful 
variants between neural cadherins 10 and 9, have been reported to be associated with 
ASD (Wang et al., 2009). Since rs3796863 is an intronic SNP, the functional 
importance of this SNP remains to be determined. After examination of immortalized 
lymphoid cells from ASD subjects and their non-idiopathic parents, Lerer et al., (2010) 
suggested that this allele may contribute to the decreased expression of CD38 in ASD 
subjects. In addition, they suggested that retinoid could be a potential therapeutic agent 
to increase CD38 expression in ASD subjects (Fig. 5; Riebold et al., 2011; Ebstein, 
2011). 
 There were significant variations in the 19 distributions of the ADI-R_C scores 
(restricted, repetitive, and stereotyped patterns of behavior) between the C/C, C/A, and 
A/A genotypes of this SNP in 252 trios and 104 HFA trios (see Fig. 3 of Munesue et al., 
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2010). The second haploblock of CD38, which included rs3796863, showed a 
significant association with HFA. The association shown by the CT haplotype of the 
second haploblock remained significant by permutation.  
 
7. Exonic rs1800561 SNP (R140W) 
 Among exon localized SNPs (Fig. 2), we detected the C4693T mutation in 
exon 3 (rs1800561) that leads to an arginine-to-tryptophan (R>W) substitution at amino 
acid 140 (R140W). This mutation is very interesting because of the functional 
abnormality in R140W-substituted CD38. R140 is located in the flexible loop (amino 
acid residues 137-141) at the mid-point of the N- and C-terminal domains between two 
helical domains (αa4 and αa5). It is the pivot point of the hinge region connecting two 
regions of the L-shaped molecule (Munesue et al., 2010). Therefore, the R140W 
mutation causes significant modifications and damage to the predicted protein structure 
in comparison with the human wild-type (R140) CD38 (see Fig. 7 of Munesue et al., 
2010). As expected, the mutant R140W-CD38 showed one-third of the ADP-ribosyl 
cyclase activity of R140 CD38 when expressed in CHO cells (Yagui et al., 1998). In 
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addition, social amnesia was not rescued by the local expression of human 
R140W-CD38, via a lentiviral infection, in the hypothalamus of CD38 knockout mice 
(Fig. 2 of Jin et al., 2007).  
 140R/W (C4693T) heterozygosity was found in 3 male subjects (2 autistic and 
1 Asperger) of the 29 ASD subjects examined (23 males and 6 females; mean age, 22.8 
± 7.6 years; prevalence, 10.3%). We examined 315 healthy unscreened control subjects 
from the Kanazawa area. Two females and 1 male were positive for the heterozygous 
mutation, representing an allelic frequency of 0.0048 (Munesue et al., 2010). This 
frequency is 10.8-fold lower than that (0.052) in the ASD patient group from the same 
residential area (p < 0.029).  
We examined whether the R140W allele co-segregated with ASD and 
ASD-related traits in 3 proband families (Fig. 2). Twenty-five members from the 3 
families of C-to-T heterozygous individuals were available for detailed clinical and 
genetic analyses. The 4693 C-to-T change was found in all proband fathers from each of 
the 3 families and in the brothers belonging to 2 families. The mutation appears to be an 
autosomal dominant trait. We identified 18 carriers in the 29 family members who 
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agreed to be tested. In all cases, the mutation was heterozygous (allelic frequency = 
0.32). The mutant allele was transcribed in all of the subjects that were tested (Munesue 
et al., 2010).  
 The family members were clinically interviewed. The younger (upper family in 
the inset of Fig. 2) and older (lower family in the inset of Fig.2) brothers of the affected 
individuals showed clinical features conforming to ASD. Two fathers in their 50’s and 
another father in his 70’s were diagnosed with ASD traits. Most of the other adults over 
50 years of age in these pedigrees had not been clinically diagnosed with ASD or any 
other psychiatric diseases and were well adapted to daily life.  
 We evaluated these individuals using the scores from the Japanese version of 
the Autism Spectrum Quotient (AQ), in which older subjects recalled behaviors from 
their 20’s. The AQ scores of 2 young male carriers in the families were relatively high 
(> 28), indicating that such carriers will manifest ASD (Fig. 3b and c). These clinical 
and self-describing evaluations are consistent with the hypothesis that the SNPs in the 
human CD38 gene may represent markers for risk alleles and that these observations 
warrant larger scale studies that have increased statistical power. 
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8. R140W mutation and oxytocin levels 
We obtained blood samples from family members of three C-to-T 
heterozygous probands to further study the connection between the human CD38 
mutation and plasma OXT or AVP levels because we have previously shown that a null 
mutation of CD38 resulted in the selective decrease of plasma OXT levels in mice (Jin 
et al., 2007). In addition, low levels of OXT have been reported in autistic children 
(Modahl et al., 1998). Plasma OXT levels in the carriers of the R140W mutation (161.3 
± 26.5 pg/ml; n = 12) were lower than those in the relatives of non-carriers (345.8 ± 
61.3 pg/ml; n = 10; p < 0.01) (Fig. 4a, c, e). The OXT levels of 3 probands and 2 
brothers with the R140W SNP were compared with those of ASD subjects lacking the 
R140W mutation. The OXT plasma concentrations of the five R140W carriers (79.2 ± 
16.6 pg/ml; n = 5; Munesue et al., 2010) were lower than those of ASD subjects lacking 
the mutation (147.7 ± 15.0 pg/ml; p < 0.01; n = 26). Furthermore, the OXT levels of 
carrier ASD individuals were significantly lower than those in 101 control adults (198.2 
± 24.7 pg/ml; p < 0.01, n = 101).  
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Interestingly, the OXT levels in control carriers of the R140W allele were not 
lower when compared with healthy subjects (Fig. 3a). The reason for this is unclear. 
Furthermore, as expected, there was no difference in the AVP levels of CD38 mutation 
carriers and non-carriers within the same pedigrees (Fig. 4 b, d, f).  
 
9. Involvement of CD38 in the pathophysiology of ASD and additional prospectives 
Recent genetic and biological studies suggest that defects in OXT signaling 
confer vulnerability to ASD (Lim and Young, 2006). CD38 SNPs may provide a genetic 
basis for the cases of ASD that arise from the disruption of OXT signaling. The R140W 
SNP occurs relatively frequently in the Asian population (see Munesue et al., 2010), 
while we recently found only one heterozygous ASD patient with this SNP in a screen 
of AGRE samples from 551 white (non-Hispanic and non-Latino) subjects. These 
results suggest that the mutation is a risk factor of Asian ASD. The association study 
using Tag SNPs showed one SNP (rs3796863) in CD38 that positively correlated with 
American HFA and low functioning ASD in Israel. Therefore, it is possible that CD38 
SNPs may provide a genetic basis for some ASDs, and therefore warrants further 
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investigation.  
Our preliminary studies suggest that a subgroup of ASD subjects with the 
R140W SNP and intelligence impairments may be effectively treated with OXT  
(Munesue et al., 2010), and these data lay the groundwork for evidence-based treatment 
of ASD by OXT administration. It is clear that a subgroup of ASD subjects with low 
plasma OXT levels could be a potential group that would benefit from OXT 
replacement therapy. However, low OXT levels are not only caused by CD38 SNPs but 
are also caused by other unknown reasons (Fig. 5). In addition, control carriers of the 
R140W allele did not have lower OXT levels (Fig. 3). It is unclear whether clinically 
unaffected carriers with this mutant allele may be influenced by compensatory factors 
for ASD. Altogether, these data support the existence of mechanisms of ASD 





 We have reviewed recent studies that have examined the neuroendocrinological 
roles of cADPR and CD38 on the secretion of OXT in the mouse and human 
hypothalamus. There is increasing evidence for the critical role of CD38 in social 
behavior in mice and humans. Therefore, CD38 defects in the OXT signal system may 
be involved in the pathophysiology of ASD. However, many fundamental questions 
about the CD38/ OXT/ OXTR pathway and ASD remain unanswered. First, it is 
unknown whether CD38 activity is sensitive to environmental and social contexts. 
Recently, Kiss et al. (2011) reported that CD38 may contribute to the general secretion 
of OXT but that CD38 may not be related to OXT secretion upon psychological 
(empathy) stimulation. Second, it is unknown if the association of CD38 with ASD 
suggests a heightened susceptibility for immunological irregularity in individuals with 
ASD. Finally, the identities of additional molecules that interact with CD38 to regulate 
OXT secretion remain unknown.  
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 Figure legends 
Fig. 1. 
A schematic representation of oxytocin (OXT) release without depolarization, via the 
calcium (red dots) amplification signal of Ca2+-induced Ca2+-release (CICR) regulated 
by cyclic ADP-ribose (cADPR). CD38 and ADP-ribosyl cyclase activity in 
OXT-producing neurons in the hypothalamus (yellow) are regulated by protein kinase C 
(PKC) and can catalyze the conversion of cADPR from β-NAD+ either intracellularly or 
extracellularly. cADPR, together with heat, can activate TRPM2 cation channels and 
facilitate the Ca2+ influx and Ca2+ release from ryanodine receptors (RyR). Ca2+ is 
released (green) from intracellular Ca2+ pools. OXT is released by the increased 
intracellular Ca2+ concentrations and is necessary for successful social interactions. 
 
Fig. 2. 
The genomic structure and single nucleotide polymorphisms of the human CD38 gene 
located on chromosome 4 in the p15 region with 8 exons. Locations of SNPs in the 
introns (upper) and exons (lower). Numbering of the nucleotides starts at the A of the 
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initial methionine (ATG) codon and refers to the GenBank accession number D84284. 
Major allele/ minor allele. The amino acid substitutions at the codon numbers of each 
SNP are shown. The number of control subjects (C) or ASD patients (P) with each 
exonic SNP, detected in the 57 family members of 3 ASD individuals, is shown. Inset 
shows the pedigrees of the 2 ASD individuals (arrows) carrying the R140W allele (red). 
Closed symbols represent individuals with the SNP. ASD patients in the lower family 
specified with a red arrow underwent nasal OXT treatment. 
 
Fig. 3. 
Plasma oxytocin (OXT) concentrations and autism-spectrum quotient (AQ) score. (a) A 
plot of the plasma OXT levels from 100 healthy control individuals with (red) or 
without (blue) the R140W allele. Note that the plasma OXT level in the R140W carriers 
of the non-idiopathic control group is not low. (b) AQ score in family members of the 
three family backgrounds with the R140W allele, together with typical ASD and control 
subjects. Assessment groups were: R140W: n = 14 family members with the 
mono-allelic R140W mutation; R140: n = 7 persons without the mutation in the families. 
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The mean or standard error (SE) and standard deviation (SD) ranges of AQ scores are 
shown. Note that 5 individuals show an intermediate score above the control range but 
below the ASD score (28). The score of individuals with R140W is higher than those 
without (one-way ANOVA, p < 0.05). (c) A plot of the AQ scores of each family 
member with or without the R140W SNP according to age. No significance was found 
between three generations (20 < age < 40, 40 < age < 60 and 60 < age) by two-way 
ANOVA. The scores of the males are significantly higher than those of the females (p < 
0.05). Circles indicate females, and diamonds indicate males. (d) Plasma oxytocin levels 
of the ASD patient who was administered nasal OXT (a member of the family from the 
inset of Fig. 2) at the beginning of treatment (red circle) and healthy males (diamonds) 
are plotted as a function of age. 
 
Fig. 4.  
Plasma oxytocin and vasopressin levels in family members. Plasma concentrations of 
OXT (a) and AVP (b) levels in family members with (R140W; n = 12, red or orange 
bars) or without (R140; n = 10, green or blue bars) the heterozygous R140W allele. 
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Mean ± s.e.m. **, p < 0.01 (one-way ANOVA). OXT (c) or AVP (d) levels in the three 
families according to age. OXT (e) or AVP (f) levels as a function of AQ scores. The 
red and orange symbols and the green and blue symbols indicate levels from persons 
with or without the R140W mutation, respectively. Circles denote females and 
diamonds or squares denote males.   
 
Fig. 5.  
Model of how single nucleotide polymorphisms (SNPs) lead to autism spectrum 
disorder (ASD) or not (non-ASD). rs3796863 and rs1800561 (R140W) SNPs may cause 
low levels of oxytocin (OXT) in the brain or plasma by lowering the expression or 
enzymatic activity of CD38. The low plasma OXT level may also be produced by other 
unknown causes. ASD may be triggered by additional strong risk factors and/or other 
weak protective factors.  Additionally, protection from ASD may also be induced by 
other weak risk factors and/or strong protective factors, including female hormones 
such as OXT. Recently, retinoids (vitamin A analogs) have shown potential as 
treatments for ASD because all-trans retinoic acids can induce CD38 transcription and 
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rescue low CD38 expressing lymphoid cells derived from ASD patients (Wbstein et al., 
2011). For the rescue of low plasma or brain OXT levels in ASD patients, OXT 
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3139   3203   3215   4092   4693    5346              6900 
C/T      T/C     A/G     C/T     C/T      A/C                C/T 
47          68       72       116     140     168                264 
R/C      V/A     E/G      T/T     R/W     I/I                  S/L    
1P         1P     1P        2P       3P        1P                0P 
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